Nclear whether glucose fluctuations have been lower in type 2 diabetic patients who had been treated longer with miglitol than in people that were treated longer with other a-GIs. Although CGM during the remedy of a-GIs had been performed under oral meal loading tests at breakfast, lunch, and dinner in patients hospitalized for four days inside the prior study [34], the diet program throughout days when SMBG was performed in our trials was dependent on every single patient. RCT trials, in which dietary habits are properly controlled, really should examine no matter if glucose fluctuations byGlucose Fluctuations and CVD Risk183 two. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative evaluation Of Diagnostic criteria in Europe. Lancet 1999; 354:617?1. three. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, NPY Y1 receptor Antagonist Gene ID Sekikawa A. Impaired glucose tolerance is usually a risk element for cardiovascular illness, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920?. four. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the threat for myocardial infarction in form two diabetic patients: meta-analysis of seven long-term research. Eur Heart J. 2004;25:10?. 5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose remedy along with the risk of cardiovascular illness and hypertension in sufferers with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486?4. 6. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007;four:84?. 7. Haubner F, Lehle K, Munzel D, Schmid C, Birnbaum DE, Preuner JG. Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 inside the diabetic endothelial cell. Biochem Biophys Res Commun. 2007;360:560?. eight. Takami S, Yamashita S, Kihara S, Kameda-Takemura K, Matsuzawa Y. Higher concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis. 1998;138:35?1. 9. Altannavch TS, Roubalova K, Kucera P, Andel M. Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and with no cytokine activation. Physiol Res. 2004;53:77?2. 10. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in individuals with form 2 diabetes PKCĪ“ Activator custom synthesis mellitus. Diabetes Res Clin Pract. 2002;55:131?. 11. Matsumoto K, Fujishima K, Moriuchi A, Saishoji H, Ueki Y. Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese sufferers with form two diabetes mellitus. Metabolism. 2010;59:320?. 12. Bluher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in individuals with impaired glucose tolerance or type II diabetes. Diabetologia. 2002;45:210?. 13. Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachorzewska-Gajewska H, Stepien A. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in males with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism. 2002;51:733?. 14. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R. Ci.